Diagnostic Testing for Diffuse Gliomas

The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response.

The evidence-based clinical practice guideline, “Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas,” informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. The guideline establishes 13 recommendations and three good practice statements to advise pathologists and treating physicians on the most appropriate methods, molecular biomarkers, and laboratory testing to include for optimal diagnosis, risk stratification and prognosis.

• Status: Active
• Published ahead of print: February 17, 2022
• Originally published: May 2022

Download the following tools and resources to help implement the guideline:

• Summary of Recommendations
• Methodology Supplement (Supplemental Digital Content)
• Teaching Presentation
• Frequently Asked Questions
• Infographic
• Algorithm

American Association of Neuropathologists

Association of Molecular Pathology

Society for Neuro-Oncology

Review more CAP evidence-based guidelines by the Center.